Goldi Kaul

Goldi Kaul, PhD, serves as Vice President and Head of External Alternative CMC Development at Boehringer Ingelheim since June 2021. Prior to that role, Goldi held various senior positions at Otsuka America, Inc., including Senior Director of Pharmaceutical Technology, where interactions with global regulatory agencies and the advancement of digital medicines were key responsibilities. Goldi's experience spans several prominent pharmaceutical companies, such as Pfizer and Wyeth Pharmaceuticals, focusing on pharmaceutical technology and the scale-up of drug development processes. Academic credentials include a Ph.D. in Pharmaceutical Sciences from Northeastern University and a Master’s degree from Jamia Hamdard.